Detection And Clinical Study Of Stem Cell Factor In Serum Of Acute Asthmatic Patients

Objectives:1.To investigate the change and significance of stem cell factor(SCF)level in serum of patients with acute exacerbation of bronchial asthma.2.To explore the relationship of asthmatic patients with acute exacerbation SCF, T-IgE, FEVl and FeNO.Methods:1.65 patients with acute exacerbation of bronchial asthma were divided into 3 groups with severity,37 normal subjects as control.65 patients with acute exacerbation of bronchial asthma were from Tianjin the first central hospital Every patient was informed about study protocol and procedures and signed informed consent form. Bronchial Asthma guidelines in accordance with the diagnostic criteria for classification of acute attack of asthma were divided.2.ELISA detection of SCF in serum:65 cases of asthma patients to take blood before treatment, The experiment was carred out in accordance to the instructions supplied with the kits.3.Detection of EOS, T-IgE in serum of asthma patients:65 cases of asthma in hospital laboratory determination of the line EOS,53 patients with asthma were treated with T-IgE determination, and was compared with the level of SCF respectively.4.Detection of FEV1%, FeNO of asthma patients 1)35 cases of asthma patients measured FEV1%,Pulmonary function was measured using Lung function cryoscope, and pulmonary function and serum concentrations of SCF to do correlation analysis.2)39 cases of asthma patients measured FeNO, and was compared with the level of SCF.Results:Acute attack of bronchial asthma in the concentration of serum SCF: SCF for the control group:661.75±49.21; SCF case group:724.91±31.29; mild group SCF:674.62±39.41; moderate group SCF:726.45±35.48; severe group SCF:768.49±58.49. The comparison between groups was statistically significant (F =11.132, P=0.000), after the LSD analysis derived:mild and moderate groups was statistically significant (P=0.029); moderate group and severe group were significantly different (P=0.044);severe group and mild group were significantly different (P=0.000). The control group compared with the case group were significantly different (P=0.000); control group and the mild group was no significant difference (P=0.886); control group and the moderate group were significantly different (P=0.015); the control group and severe group were significantly different (P=0.000).65 patients with acute exacerbation of asthma FEV1% of patients with ONE- ANOVA analysis was F=15.931, P=0.000, was statistically significant, the LSD analysis derived:mild group VS moderate group P= 0.009, statistically significant; moderate group VS severe group P=0.002, was statistically significant; mild group VS severe group P=0.000, was statistically significant. For statistical analysis of T-IgE P=0.125, not statistically significant. Statistical analysis of the serum of the EOS P=0.059, not statistically significant. FeNO values after rank test P=0.000, statistically significant, by pairwise rank sum test was between:mild group VS moderate group P=0.003, was statistically significant; mild group VS severe group P=0.000, with statistical significance; moderate group VS severe group P=0.002, was statistically significant.Acute attack of bronchial asthma with serum SCF, EOS no correlation, r=0.134, P=0.287; SCF and T-IgE had no correlation, r=0.211, P=0.129; SCF no correlation with the FEV1% pred, r=-0.369, P=0.055> 0.05; SCF was positively correlated with FeNO, r=0.447, P=0.004<0.05.Conclusions:1. The concentration of SCF maybe estimates accurately response airway inflammation changes, it may be involved in the pathogenesis of asthma.2. The concentration of SCF in serum of acute asthma patients is closely related with the severity of bronchial asthma, it maybe as an asthma diagnosis and severity assessment indicators.